Efficacy of Yasmin in premenstrual symptoms

Archives of Gynecology and Obstetrics

Volumn 275, Issue 6, 2007, Pages 433-438

  Taneepanichskul, Surasak ^a   Jaisamrarn, Unnop ^a   Phupong, Vorapong ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Drospirenone; Oral contraception; Premenstrual symptoms; WHAQ score

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENTAL CONCENTRATION; PREMENSTRUAL SYNDROME; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT DURATION; WATER RETENTION; WELLBEING; WOMEN'S HEALTH;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; PREMENSTRUAL SYNDROME;

EID: 34249002019     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-006-0280-6     Document Type: Article

References (22)

1. Anonymous (1998) An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group. Am J Obstet Gynecol 179:S2-S8
2. Apter D, Borsos A, Baumgartner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, Palmer M, Kelly S (2003) Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 8:37-51
3. Barnhart KT, Freeman EW, Sondheimer SJ (1995) A clinician's guide to the premenstrual syndrome. Med Clin North Am 79:1457-1472
4. Boerrigter PJ, Ellman H, Dolker M (1999) International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 microg and ethinyl estradiol 20 microg. Clin Ther 21:118-127
5. Borenstein J, Yu HT, Wade S, Chiou CF, Rapkin A (2003) Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 48:79-85
6. Brown C, Ling F, Wan J (2002) A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J Reprod Med 47:14-22
7. Daugherly JE (1998) Treatment strategies for premenstrual syndrome. Am Fam Physician 58:183-192
8. Dell DL (2004) Premenstrual syndrome, premenstrual dysphoric disorder, and premenstrual exacerbation of another disorder. Clin Obstet Gynecol 47:568-575
9. Endrikat J, Muller U, Dusterberg B (1997) A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 55:131-137
10. Eriksson E, Sundblad C, Lisjo P, Modigh K, Andersch B (1992) Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology 17:195-204
11. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R (2000) A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 5:124-134
12. Logue CM, Moos RH (1986) Perimenstrual symptoms: prevalence and risk factors. Psychosom Med 48:388-414
13. Moline ML (1993) Pharmacologic strategies for managing premenstrual syndrome. Clin Pharm 12:181-196
14. Moos RH (1991) Menstrual distress questionnaire manual. Western Psychological Service, Los Angeles
15. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E (1995) Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 761:311-335
16. Oelkers W (2000) Drospirenone-a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 5(Suppl3):17-24
17. Oelkers W (2004) Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 217:255-261
18. Parsey KS, Pong A (2000) An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 61:105-111
19. Severino SK, Moline ML (1989) Premenstrual syndrome: a clinician's guide. Guilford press, New York
20. Sveindottir H, Backstrom T (2000) Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 79:405-413
21. World Health Organization (WHO) (1996). Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use methods. World Health Organization, Geneva
22. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A (2005) Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106:492-501